The signalling pathways of secretases in APP processing: an OMICS approach for neuronal health
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10773/33854 |
Resumo: | The Alzheimer’s Amyloid Precursor Protein (APP), a central protein in Alzheimer´s Disease (AD), is metabolized in a highly complex fashion by a series of sequential secretases, which can lead to α, β, and γ-cleavage, accordingly. The toxic abilities of the resulting fragments are a direct consequence of the first cleaving secretase: β-secretase (BACE1) induces an amyloid cleavage while, α-secretase (ADAM10 and ADAM17) cleavage does not have the same pathological impact in AD. The latter is currently being studied as a therapeutic target for preventing or reverting the initial biochemical events of AD, as it may compete with BACE1 for APP’s first cleavage. Literature demonstrates that retinoic acid (RA) receptor (RAR) alters secretase activity, suggesting anti-amyloid effects: downregulation of Amyloid-β-peptide (Aβ) releasing secretases (β and γ-secretase) and upregulation of the beneficial α-secretase. In addition, RA reduces neuroinflammation and promotes neurite growth. To experimentally verify the impact of RA, the SH-SY5Y neuronal cell line was used. Differentiated cells were treated for 48 hours with retinoids agonists and antagonists for different RAR isoforms. Treatments suggest alterations in proteins directly associated with AD, that can be either benefitial or pathlogical, depending the RAR isoform being stimulated. The APP secretaseome was compiled and analyzed. The data from a YTH system was introduced and new potential interactors described. Targets from a holistic and systems aproach were identified as potencial interest proteins for further understanding the impact of stimulating each RAR isoform. Data from mass spectophotometry analysis of the insoluble fraction of human fibroblasts from AD patients was also introduced in the search for targets in the holistic and systems medicine perspective. Coincidentelly, some targets were found in common when compared with the APP secretase network, being possible important proteins in the context of AD neurodegeneration pathways. In conclusion, bioinformatic approaches provide global and dynamic results on molecular changes and interactions under different conditions, of particular interest for complex pathologies such as AD. Induced therapeutic changes must restore homeostasis and not only alter the specific source of the problem. The combination of bioinformatics and wet lab tools provides a putative gateway, with promising results in the specific study of effects resulting from the stimulattion of the retinoid acid receptor as a potential therapy for AD. |
id |
RCAP_fed984676bbd2325a5b888a73ddc1f91 |
---|---|
oai_identifier_str |
oai:ria.ua.pt:10773/33854 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
The signalling pathways of secretases in APP processing: an OMICS approach for neuronal healthα-secretasesβ-secretasesϒ-secretasesRetinoic acidAmyloid-beta precursor proteinAPP secretaseome networkAPP processingAmyloid-β peptideAlzheimer´s diseaseNeurodegenerationThe Alzheimer’s Amyloid Precursor Protein (APP), a central protein in Alzheimer´s Disease (AD), is metabolized in a highly complex fashion by a series of sequential secretases, which can lead to α, β, and γ-cleavage, accordingly. The toxic abilities of the resulting fragments are a direct consequence of the first cleaving secretase: β-secretase (BACE1) induces an amyloid cleavage while, α-secretase (ADAM10 and ADAM17) cleavage does not have the same pathological impact in AD. The latter is currently being studied as a therapeutic target for preventing or reverting the initial biochemical events of AD, as it may compete with BACE1 for APP’s first cleavage. Literature demonstrates that retinoic acid (RA) receptor (RAR) alters secretase activity, suggesting anti-amyloid effects: downregulation of Amyloid-β-peptide (Aβ) releasing secretases (β and γ-secretase) and upregulation of the beneficial α-secretase. In addition, RA reduces neuroinflammation and promotes neurite growth. To experimentally verify the impact of RA, the SH-SY5Y neuronal cell line was used. Differentiated cells were treated for 48 hours with retinoids agonists and antagonists for different RAR isoforms. Treatments suggest alterations in proteins directly associated with AD, that can be either benefitial or pathlogical, depending the RAR isoform being stimulated. The APP secretaseome was compiled and analyzed. The data from a YTH system was introduced and new potential interactors described. Targets from a holistic and systems aproach were identified as potencial interest proteins for further understanding the impact of stimulating each RAR isoform. Data from mass spectophotometry analysis of the insoluble fraction of human fibroblasts from AD patients was also introduced in the search for targets in the holistic and systems medicine perspective. Coincidentelly, some targets were found in common when compared with the APP secretase network, being possible important proteins in the context of AD neurodegeneration pathways. In conclusion, bioinformatic approaches provide global and dynamic results on molecular changes and interactions under different conditions, of particular interest for complex pathologies such as AD. Induced therapeutic changes must restore homeostasis and not only alter the specific source of the problem. The combination of bioinformatics and wet lab tools provides a putative gateway, with promising results in the specific study of effects resulting from the stimulattion of the retinoid acid receptor as a potential therapy for AD.A proteína precursora da Doença de Alzheimer (APP), uma proteína central na Doença de Alzheimer (AD), é metabolizada de forma altamente complexa por uma série de secretases, que podem levar às clivagens α, β e γ. As capacidades tóxicas dos fragmentos resultantes são uma consequência direta da primeira clivagem: a β-secretase (BACE1) induz uma clivagem amiloide enquanto, contrariamente, a clivagem da α-secretase (ADAM10 e ADAM17) não tem o mesmo impacto patológico na AD. As α-secretases são, há algum tempo, alvo de estudo como um potencial alvo terapêutico para prevenir ou reverter os eventos bioquímicos iniciais da AD, uma vez que podem competir com BACE1 pela primeira clivagem de APP. A literatura demonstra que o recetor (RAR) do ácido retinoico (RA) altera a atividade das secretases, promovendo efeitos anti amiloides: regulação negativa do peptídeo β-amiloide (Aβ), libertado pelas secretases β e γ, e regulação positiva da α-secretase. Além disso, o RA reduz a neuroinflamação e promove o crescimento de neurites. Para verificar experimentalmente o impacto do RA, a linha de células neuronal SH-SY5Y foi usada. As células foram diferenciadas e tratadas durante 48 horas com retinoides agonistas e antagonistas de diferentes isoformas do RAR. O tratamento sugere alterações nas proteínas diretamente associadas à AD, que podem ser benéficas ou patológicas, dependendo da isoforma do RAR estimulada. Posteriormente, o secretaseoma da APP foi obtido e analisado. Dados experimentais obtidos por técnicas de dupla hibridação em leveduras foram incorporados potenciando novos interactores. Os alvos, a partir de uma abordagem holística e sistémica, foram identificados como proteínas de potencial interesse para a melhor perceção do impacto da estimulação dos RAR e da diferença decorrente de cada uma de suas isoformas individuais. Dados da análise de espectrofotometria de massa da fração insolúvel de fibroblastos humanos com AD também foram introduzidos na pesquisa por alvos do ponto de vista holístico e de medicina de sistemas. Coincidentemente, alguns alvos encontram-se em comum quando comparados com a rede de secretases da APP apresentando-se como possíveis pontos de importante valor no contexto das vias de neurodegeneração da AD. Em conclusão, as abordagens bioinformáticas fornecem resultados globais e dinâmicos sobre mudanças moleculares e interações proteicas sob diferentes condições, de particular interesse para patologias complexas como a AD. As alterações terapêuticas induzidas devem ser compatíveis com a homeostase e não apenas alterar a origem específica do problema. A combinação de bioinformática e ferramentas de wet lab fornecem uma potencial forma de abordagem para patologias complexas, com resultados promissores no estudo específico dos efeitos resultantes da estimulação dos RAR como uma potencial terapia na AD.2023-07-27T00:00:00Z2021-07-22T00:00:00Z2021-07-22info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10773/33854engVitória, José João Mendonçainfo:eu-repo/semantics/embargoedAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-02-22T12:05:09Zoai:ria.ua.pt:10773/33854Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:05:11.978730Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
The signalling pathways of secretases in APP processing: an OMICS approach for neuronal health |
title |
The signalling pathways of secretases in APP processing: an OMICS approach for neuronal health |
spellingShingle |
The signalling pathways of secretases in APP processing: an OMICS approach for neuronal health Vitória, José João Mendonça α-secretases β-secretases ϒ-secretases Retinoic acid Amyloid-beta precursor protein APP secretaseome network APP processing Amyloid-β peptide Alzheimer´s disease Neurodegeneration |
title_short |
The signalling pathways of secretases in APP processing: an OMICS approach for neuronal health |
title_full |
The signalling pathways of secretases in APP processing: an OMICS approach for neuronal health |
title_fullStr |
The signalling pathways of secretases in APP processing: an OMICS approach for neuronal health |
title_full_unstemmed |
The signalling pathways of secretases in APP processing: an OMICS approach for neuronal health |
title_sort |
The signalling pathways of secretases in APP processing: an OMICS approach for neuronal health |
author |
Vitória, José João Mendonça |
author_facet |
Vitória, José João Mendonça |
author_role |
author |
dc.contributor.author.fl_str_mv |
Vitória, José João Mendonça |
dc.subject.por.fl_str_mv |
α-secretases β-secretases ϒ-secretases Retinoic acid Amyloid-beta precursor protein APP secretaseome network APP processing Amyloid-β peptide Alzheimer´s disease Neurodegeneration |
topic |
α-secretases β-secretases ϒ-secretases Retinoic acid Amyloid-beta precursor protein APP secretaseome network APP processing Amyloid-β peptide Alzheimer´s disease Neurodegeneration |
description |
The Alzheimer’s Amyloid Precursor Protein (APP), a central protein in Alzheimer´s Disease (AD), is metabolized in a highly complex fashion by a series of sequential secretases, which can lead to α, β, and γ-cleavage, accordingly. The toxic abilities of the resulting fragments are a direct consequence of the first cleaving secretase: β-secretase (BACE1) induces an amyloid cleavage while, α-secretase (ADAM10 and ADAM17) cleavage does not have the same pathological impact in AD. The latter is currently being studied as a therapeutic target for preventing or reverting the initial biochemical events of AD, as it may compete with BACE1 for APP’s first cleavage. Literature demonstrates that retinoic acid (RA) receptor (RAR) alters secretase activity, suggesting anti-amyloid effects: downregulation of Amyloid-β-peptide (Aβ) releasing secretases (β and γ-secretase) and upregulation of the beneficial α-secretase. In addition, RA reduces neuroinflammation and promotes neurite growth. To experimentally verify the impact of RA, the SH-SY5Y neuronal cell line was used. Differentiated cells were treated for 48 hours with retinoids agonists and antagonists for different RAR isoforms. Treatments suggest alterations in proteins directly associated with AD, that can be either benefitial or pathlogical, depending the RAR isoform being stimulated. The APP secretaseome was compiled and analyzed. The data from a YTH system was introduced and new potential interactors described. Targets from a holistic and systems aproach were identified as potencial interest proteins for further understanding the impact of stimulating each RAR isoform. Data from mass spectophotometry analysis of the insoluble fraction of human fibroblasts from AD patients was also introduced in the search for targets in the holistic and systems medicine perspective. Coincidentelly, some targets were found in common when compared with the APP secretase network, being possible important proteins in the context of AD neurodegeneration pathways. In conclusion, bioinformatic approaches provide global and dynamic results on molecular changes and interactions under different conditions, of particular interest for complex pathologies such as AD. Induced therapeutic changes must restore homeostasis and not only alter the specific source of the problem. The combination of bioinformatics and wet lab tools provides a putative gateway, with promising results in the specific study of effects resulting from the stimulattion of the retinoid acid receptor as a potential therapy for AD. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-07-22T00:00:00Z 2021-07-22 2023-07-27T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10773/33854 |
url |
http://hdl.handle.net/10773/33854 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/embargoedAccess |
eu_rights_str_mv |
embargoedAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137707126947840 |